HIPEC with mitomycin C after surgery for colon cancer in the belly
Part of Cancer, Digestive system clinical trials.
This study looks at adding a heated medicine treatment (HIPEC with mitomycin C) during surgery to treat colon cancer that has spread to the lining of the abdomen (peritoneum). It aims to improve outcomes after surgeons remove visible tumor completely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your colon cancer has been confirmed under the microscope as colon adenocarcinoma (not signet ring type that makes up most of the tumor).
- You do not have cancer spread outside the belly (like in liver, lungs, or distant lymph nodes).
- You have peritoneal (belly lining) metastases of limited size, with PCI 20 or less, confirmed during surgery.
- Surgeons can remove all visible tumor in the belly (complete cytoreduction, CCS-0), confirmed during surgery.
- You are an adult (over 18) and can tolerate major surgery: ASA 1–3 and ECOG 0–1, with acceptable heart/lung/kidney/liver blood test status.
- You must be able to have standard chemo around the surgery and you will give written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a specialized surgery called HIPEC (heat-treated chemotherapy placed in the belly) can improve outcomes for people with advanced stomach cancer that has reached the lining of the abdomen. It’s given after you’ve already had standard chemotherapy, aiming to better control disease in the belly.
This trial tests a new way to deliver chemotherapy directly into the abdomen (called PIPAC) for people with cancer spread to the lining of the belly. It uses the drug mitomycin and is for patients who cannot have standard surgery or heated chemotherapy.
This study tries to better predict how well patients do after heated chemotherapy placed in the abdomen during surgery for stomach or colon cancer that has spread to the lining of the abdomen. It may help doctors choose the best treatment plan and timing for future patients.
This Phase 2 study tests whether a modified chemotherapy given inside the abdomen soon after surgery is practical and safe. It may help people with appendix or colon cancer that has spread within the abdomen (peritoneal carcinomatosis) by targeting cancer cells after tumor removal.
This Phase 2 study tests whether spraying chemotherapy into the abdomen (through a small procedure) after colon cancer surgery can lower the chance the cancer comes back. It is meant for people with high-risk tumor features but who have had surgery and have no proven relapse yet.
This Phase 2 study compares two ways of dosing chemotherapy—one fixed (flat) dose versus dosing based on your weight—during CRS/HIPEC, a surgery-based treatment for certain cancers in the belly. It looks to see whether the dosing approach affects safety and effectiveness for people with peritoneal cancer spread.
Hear when a new Peritoneal Carcinomatosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.